Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Famciclovir - Novartis

Drug Profile

Famciclovir - Novartis

Alternative Names: AK-120; BRL-42810; Famvir

Latest Information Update: 12 Jul 2020

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator GlaxoSmithKline
  • Developer Asahi Kasei Pharma Corp; Astellas Pharma; GlaxoSmithKline; Maruho; Novartis; Solvay
  • Class Antivirals; Nucleosides; Purines; Small molecules
  • Mechanism of Action DNA-directed DNA polymerase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Herpes simplex virus infections; Herpes zoster; Herpesvirus infections
  • No development reported Herpes labialis
  • Discontinued Epstein-Barr virus infections; Hepatitis B

Most Recent Events

  • 21 Feb 2019 Registered for Herpes simplex virus infections (Recurrent) in Japan (PO)
  • 01 Dec 2018 Preregistration for Herpes simplex virus infections (Recurrent) in Japan (PO) before February 2019
  • 31 Oct 2018 Maruho completes a phase III trial for Herpes simplex virus infections (Recurrent) in Japan (PO) (JapicCTI-163223)
Restricted Access

If your organization has a subscription then there are several options available to help you access AdisInsight while working remotely. Contact us at AsktheExpert.AdisInsight@springer.com to find out more.
Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top